399 related articles for article (PubMed ID: 29160922)
1. IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance.
Selfe J; Goddard NC; McIntyre A; Taylor KR; Renshaw J; Popov SD; Thway K; Summersgill B; Huddart RA; Gilbert DC; Shipley JM
J Pathol; 2018 Feb; 244(2):242-253. PubMed ID: 29160922
[TBL] [Abstract][Full Text] [Related]
2. Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance.
Mueller T; Mueller LP; Luetzkendorf J; Voigt W; Simon H; Schmoll HJ
Tumour Biol; 2006; 27(2):71-83. PubMed ID: 16557044
[TBL] [Abstract][Full Text] [Related]
3. Influence of Nodal signalling on pluripotency factor expression, tumour cell proliferation and cisplatin-sensitivity in testicular germ cell tumours.
Harpelunde Poulsen K; Nielsen JE; Grønkær Toft B; Joensen UN; Rasmussen LJ; Blomberg Jensen M; Mitchell RT; Juul A; Rajpert-De Meyts E; Jørgensen A
BMC Cancer; 2020 Apr; 20(1):349. PubMed ID: 32326899
[TBL] [Abstract][Full Text] [Related]
4. The PDGFRβ-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors.
Juliachs M; Muñoz C; Moutinho CA; Vidal A; Condom E; Esteller M; Graupera M; Casanovas O; Germà JR; Villanueva A; Viñals F
Clin Cancer Res; 2014 Feb; 20(3):658-67. PubMed ID: 24277456
[TBL] [Abstract][Full Text] [Related]
5. Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours.
Rudolph C; Melau C; Nielsen JE; Vile Jensen K; Liu D; Pena-Diaz J; Rajpert-De Meyts E; Rasmussen LJ; Jørgensen A
Cell Oncol (Dordr); 2017 Aug; 40(4):341-355. PubMed ID: 28536927
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
Gohr K; Hamacher A; Engelke LH; Kassack MU
BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer.
Nitzsche B; Gloesenkamp C; Schrader M; Hoffmann B; Zengerling F; Balabanov S; Honecker F; Höpfner M
Br J Cancer; 2012 Nov; 107(11):1853-63. PubMed ID: 23169338
[TBL] [Abstract][Full Text] [Related]
8. Seladin-1 and testicular germ cell tumours: new insights into cisplatin responsiveness.
Nuti F; Luciani P; Marinari E; Erdei E; Bak M; Deledda C; Rosati F; Mazzinghi B; Danza G; Stoop H; Looijenga LH; Peri A; Serio M; Krausz C
J Pathol; 2009 Dec; 219(4):491-500. PubMed ID: 19844922
[TBL] [Abstract][Full Text] [Related]
9. Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine.
Albany C; Hever-Jardine MP; von Herrmann KM; Yim CY; Tam J; Warzecha JM; Shin L; Bock SE; Curran BS; Chaudhry AS; Kim F; Sandusky GE; Taverna P; Freemantle SJ; Christensen BC; Einhorn LH; Spinella MJ
Oncotarget; 2017 Jan; 8(2):2949-2959. PubMed ID: 27936464
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of SPRY4 and SPRY4-IT1 inhibits cell growth and phosphorylation of Akt in human testicular germ cell tumours.
Das MK; Furu K; Evensen HF; Haugen ØP; Haugen TB
Sci Rep; 2018 Feb; 8(1):2462. PubMed ID: 29410498
[TBL] [Abstract][Full Text] [Related]
12. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
[TBL] [Abstract][Full Text] [Related]
13. NANOG controls testicular germ cell tumour stemness through regulation of MIR9-2.
Cardenas RP; Zyoud A; McIntyre A; Alberio R; Mongan NP; Allegrucci C
Stem Cell Res Ther; 2024 May; 15(1):128. PubMed ID: 38693576
[TBL] [Abstract][Full Text] [Related]
14. The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo.
Jostes S; Nettersheim D; Fellermeyer M; Schneider S; Hafezi F; Honecker F; Schumacher V; Geyer M; Kristiansen G; Schorle H
J Cell Mol Med; 2017 Jul; 21(7):1300-1314. PubMed ID: 28026145
[TBL] [Abstract][Full Text] [Related]
15. miRNA-302s may act as oncogenes in human testicular germ cell tumours.
Das MK; Evensen HSF; Furu K; Haugen TB
Sci Rep; 2019 Jun; 9(1):9189. PubMed ID: 31235829
[TBL] [Abstract][Full Text] [Related]
16. Influence of vitamin D on cisplatin sensitivity in testicular germ cell cancer-derived cell lines and in a NTera2 xenograft model.
Jørgensen A; Blomberg Jensen M; Nielsen JE; Juul A; Rajpert-De Meyts E
J Steroid Biochem Mol Biol; 2013 Jul; 136():238-46. PubMed ID: 23098692
[TBL] [Abstract][Full Text] [Related]
17. Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours.
Cierna Z; Miskovska V; Roska J; Jurkovicova D; Pulzova LB; Sestakova Z; Hurbanova L; Machalekova K; Chovanec M; Rejlekova K; Svetlovska D; Kalavska K; Kajo K; Babal P; Mardiak J; Ward TA; Mego M; Chovanec M
BMC Cancer; 2020 Jan; 20(1):17. PubMed ID: 31906898
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
20. Revisiting DNA damage repair, p53-mediated apoptosis and cisplatin sensitivity in germ cell tumors.
Cavallo F; Feldman DR; Barchi M
Int J Dev Biol; 2013; 57(2-4):273-80. PubMed ID: 23784838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
